Model 1 (n = 251) | Model 2 (n = 280) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Crude OR | 95% CI | p-value | Adjusted OR | 95% CI | p-value | Adjusted OR | 95% CI | p-value | |
Female gender | 1.77 | (1.06-2.97) | 0.029 | 1.26 | (0.69-2.27) | 0.452 | 1.16 | (0.65-2.05) | 0.615 |
Age | 1.03 | (0.96-1.09) | 0.421 | 1.03 | (0.96-1.11) | 0.425 | 1.02 | (0.95-1.09) | 0.564 |
Predisaster MHS utilization | 1.40 | (0.78-2.52) | 0.262 | 1.06 | (0.55-2.06) | 0.865 | 0.97 | (0.52-1.84) | 0.935 |
T1 PTSD (UCLA PTSD-RI) | 2.49 | (1.65-3.76) | <0.001 | 1.04 | (0.48-2.25) | 0.918 | |||
T1 Mental distress (SCL-8) | 3.37 | (2.06-5.52) | <0.001 | 2.81 | (1.16-6.78) | 0.022 | |||
T1 Somatic symptoms (CSSI-8) | 2.95 | (1.67-5.21) | <0.001 | 1.21 | (0.56-2.63) | 0.628 | |||
T2 PTSD (UCLA PTSD-RI) | 2.61 | (1.68-4.05) | <0.001 | 1.82 | (0.87-3.79) | 0.112 | |||
T2 Mental distress (SCL-8) | 2.35 | (1.48-3.73) | <0.001 | 0.67 | (0.29-1.53) | 0.338 | |||
T2 Somatic symptoms (CSSI-8) | 5.54 | (2.79-10.99) | <0.001 | 4.35 | (1.75-10.83) | 0.002 |